↓ Skip to main content

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database

Overview of attention for article published in Radiation Oncology, June 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
Published in
Radiation Oncology, June 2018
DOI 10.1186/s13014-018-1057-3
Pubmed ID
Authors

Nikola Cihoric, Eugenia Vlaskou Badra, Alexandros Tsikkinis, Vikas Prasad, Stephanie Kroeze, Ivan Igrutinovic, Branislav Jeremic, Marcus Beck, Sebastian Zschaeck, Peter Wust, Pirus Ghadjar

Abstract

The goal of this study is to evaluate the status and future perspectives of clinical trials on positron emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes. The www.ClinicalTrials.gov database was searched on the 20th of January 2017 for all trials containing terms describing "prostate cancer" (prostate, prostatic, malignant, malignancy, cancer, tumor) and "positron emission tomography". In total 167 trials were identified. Trials that included diseases other than PCa were excluded (n = 27; 16%). Furthermore, we excluded trials (n = 4, 2%) withdrawn prior to first patient enrollment. The remaining trials (n = 137, 82%) were selected for further manual classification analysis. One hundred thirty-seven trials were detected and analyzed. Majority of trials were in "active" recruitment status (n = 46, 34%) followed by trials that had been "completed" - (n = 34, 25%) and trials with "closed recruitment but active follow-up" (n = 23, 17%). Phase 1 and 2 comprised 46% of the complete trial portfolio. Locally confined disease was of major interest (n = 46, 34%), followed by metastatic disease - not otherwise specified (n = 43, 13%). Evaluation of PET was the primary goal of the trial in 114 (83%) cases. Most of the trials evaluated only one agent (n = 122, 89%). Choline and PSMA represented two major groups (total 50%) and they were equally distributed across trial portfolio with 25% (n = 34) each. PSMA trials showed the highest average annual growth rate of 56%. The trials were conducted in 17 countries. The scientific community is showing a strong and ever-growing interest in the field and we expect that in the coming years, more phase III trials will be initiated ultimately delivering the required Level 1 evidence.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 30%
Researcher 6 26%
Other 2 9%
Student > Ph. D. Student 1 4%
Student > Doctoral Student 1 4%
Other 2 9%
Unknown 4 17%
Readers by discipline Count As %
Medicine and Dentistry 8 35%
Agricultural and Biological Sciences 2 9%
Computer Science 2 9%
Business, Management and Accounting 1 4%
Economics, Econometrics and Finance 1 4%
Other 3 13%
Unknown 6 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2018.
All research outputs
#20,522,137
of 23,090,520 outputs
Outputs from Radiation Oncology
#1,696
of 2,078 outputs
Outputs of similar age
#287,414
of 328,114 outputs
Outputs of similar age from Radiation Oncology
#29
of 35 outputs
Altmetric has tracked 23,090,520 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,078 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,114 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.